Evidence map›Paper›PMID 38658567›Full record

ArticleCell death & disease2024

ATF3 characterizes aggressive drug-tolerant persister cells in HGSOC.

Kathrin Böpple, Yaara Oren, Whitney S Henry, Meng Dong, Sandra Weller, Julia Thiel, Markus Kleih, Andrea Gaißler, Damaris Zipperer, Hans-Georg Kopp and 5 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 3 countries.

Kathrin BöppleDr. Margarete Fischer-Bosch - Institute of Clinical Pharmacology and University of Tuebingen, Auerbachstr. 112, 70376, Stuttgart, Germany. Kathrin.Boepple@bosch-health-campus.com.ORCID 0009-0007-5154-0444
Yaara OrenDepartment of Human Molecular Genetics & Biochemistry, Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel.
Whitney S HenryWhitehead Institute for Biomedical Research, 455 Main St., Cambridge, MA, 02142, USA.
Meng DongDr. Margarete Fischer-Bosch - Institute of Clinical Pharmacology and University of Tuebingen, Auerbachstr. 112, 70376, Stuttgart, Germany.ORCID 0000-0002-6434-1678
Sandra WellerDr. Margarete Fischer-Bosch - Institute of Clinical Pharmacology and University of Tuebingen, Auerbachstr. 112, 70376, Stuttgart, Germany.
Julia ThielDr. Margarete Fischer-Bosch - Institute of Clinical Pharmacology and University of Tuebingen, Auerbachstr. 112, 70376, Stuttgart, Germany.
Markus KleihDr. Margarete Fischer-Bosch - Institute of Clinical Pharmacology and University of Tuebingen, Auerbachstr. 112, 70376, Stuttgart, Germany.
Andrea GaißlerDr. Margarete Fischer-Bosch - Institute of Clinical Pharmacology and University of Tuebingen, Auerbachstr. 112, 70376, Stuttgart, Germany.
Damaris ZippererDr. Margarete Fischer-Bosch - Institute of Clinical Pharmacology and University of Tuebingen, Auerbachstr. 112, 70376, Stuttgart, Germany.
Hans-Georg KoppRobert Bosch Hospital, Auerbachstr. 110, 70376, Stuttgart, Germany.
Yael AylonWeizmann Institute of Science, 234 Herzl St, Rehovot, Israel.ORCID 0000-0001-5821-9548
Moshe OrenWeizmann Institute of Science, 234 Herzl St, Rehovot, Israel.ORCID 0000-0003-4311-7172
Frank EssmannDr. Margarete Fischer-Bosch - Institute of Clinical Pharmacology and University of Tuebingen, Auerbachstr. 112, 70376, Stuttgart, Germany.
Chunguang LiangDepartment of Bioinformatics, Biocenter Am Hubland, University of Wuerzburg, 97074, Wuerzburg, Germany. chunguang.liang@med.uni-jena.de.ORCID 0000-0002-0305-2522
Walter E AulitzkyRobert Bosch Hospital, Auerbachstr. 110, 70376, Stuttgart, Germany.ORCID 0000-0003-2165-0187
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology · DERobert Bosch Hospital · DEWeizmann Institute of Science · ILTel Aviv University · ILUniversity of Würzburg · DEWhitehead Institute for Biomedical Research · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-grade serous ovarian cancer (HGSOC) represents the most common and lethal subtype of ovarian cancer. Despite initial response to platinum-based standard therapy, patients commonly suffer from relapse that likely originates from drug-tolerant persister (DTP) cells. We generated isogenic clones of treatment-naïve and cisplatin-tolerant persister HGSOC cells. In addition, single-cell RNA sequencing of barcoded cells was performed in a xenograft model with HGSOC cell lines after platinum-based therapy. Published single-cell RNA-sequencing data from neo-adjuvant and non-treated HGSOC patients and patient data from TCGA were analyzed. DTP-derived cells exhibited morphological alterations and upregulation of epithelial-mesenchymal transition (EMT) markers. An aggressive subpopulation of DTP-derived cells showed high expression of the stress marker ATF3. Knockdown of ATF3 enhanced the sensitivity of aggressive DTP-derived cells to cisplatin-induced cell death, implying a role for ATF3 stress response in promoting a drug tolerant persister cell state. Furthermore, single cell lineage tracing to detect transcriptional changes in a HGSOC cell line-derived xenograft relapse model showed that cells derived from relapsed solid tumors express increased levels of EMT and multiple endoplasmic reticulum (ER) stress markers, including ATF3. Single cell RNA sequencing of epithelial cells from four HGSOC patients also identified a small cell population resembling DTP cells in all samples. Moreover, analysis of TCGA data from 259 HGSOC patients revealed a significant progression-free survival advantage for patients with low expression of the ATF3-associated partial EMT genes. These findings suggest that increased ATF3 expression together with partial EMT promote the development of aggressive DTP, and thereby relapse in HGSOC patients.

Indexed as

Activating Transcription Factor 3CisplatinDrug Resistance, NeoplasmEpithelial-Mesenchymal TransitionOvarian NeoplasmsAnimalsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMiceXenograft Model Antitumor AssaysActivating Transcription Factor 3ATF3 protein, humanCisplatin

Identifiers

PMID38658567
PMCPMC11043376
OpenAlexW4395072272

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.